Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pimicotinib and Food/Omeprazole Effect in Healthy Subjects
NCT06322706Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 2 more. Started Mar 2024; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06322706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322706.